MLXIPL and metabolic disease: For example, elevating the concentrations of EV miR-27b, miR-122, and miR-34a, which are recognised for activating ChREBP and SREBP1c, aids in identifying patients whose metabolic disorders are mostly attributable to hepatic lipogenesis rather than AMPK activation.